Taysha Gene Therapies TSHA
$3.72 −$0.05 (-1.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.71 -0.27%
Open$3.67
Prev close$3.77
Day range$3.60 – $3.80
Volume3.15M
Market cap$1.21B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$0.00-100.0% YoY
Operating profit-$50.78M-89.8% YoY
Net profit-$46.64M-73.5% YoY
Diluted EPS-$0.13-44.4% YoY
Free cash flow-$40.42M-100.3% YoY
Operating cash flow-$40.43M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-2,854.9%
Net margin-2,728.0%
Return on equity-47.1%
Return on assets-37.2%
Return on invested capital-42.7%
Current ratio17.76
Liabilities / assets17.7%
Cash & investments$455.41M
Total debt$55.55M
Net cash (debt)$399.86M
Income statement
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $0.00 | – | – | $0.00 |
| Total Operating Revenue | $0.00 | $0.00 | $9.77M | $5.49M | $0.00 |
| Operating Expense | $50.78M | $43.49M | $120.27M | $33.79M | $34.02M |
| Selling and Admin Expenses | $12.15M | $9.68M | $33.87M | $8.83M | $8.28M |
| -General & Admin Expense | $12.15M | $9.68M | $33.87M | $8.83M | $8.28M |
| Research & Development | $38.64M | $33.81M | $86.40M | $24.95M | $25.75M |
| Operating Profit | -$50.78M | -$43.49M | -$110.50M | -$28.30M | -$34.02M |
| Net Non-Operating Interest Income (Expense) | $2.32M | $2.58M | $9.16M | $2.86M | $3.15M |
| Non-Operating Interest Income | $2.33M | $2.59M | $9.22M | $2.87M | $3.17M |
| Non-Operating Interest Expense | $6,000.00 | $9,000.00 | $63,000.00 | $12,000.00 | $15,000.00 |
| Other Income (Expense) | $1.82M | -$1.50M | -$7.66M | -$2.41M | -$1.86M |
| Special Income (Charges) | $3.43M | – | $0.00 | $0.00 | $0.00 |
| -Less:Other Special Charges | -$3.43M | – | – | – | – |
| Other Non-Operating Income (Expenses) | -$1.61M | -$1.50M | -$6.46M | -$1.67M | -$1.57M |
| Pretax Profit | -$46.64M | -$42.41M | -$109.00M | -$27.85M | -$32.73M |
| Net Profit | -$46.64M | -$42.41M | -$109.00M | -$27.85M | -$32.73M |
| Profit from Continuing Operations | -$46.64M | -$42.41M | -$109.00M | -$27.85M | -$32.73M |
| Net Income to Parent Company | -$46.64M | -$42.41M | -$109.00M | -$27.85M | -$32.73M |
| Net Income to Common Stockholders | -$46.64M | -$42.41M | -$109.00M | -$27.85M | -$32.73M |
| Basic EPS | -$0.13 | -$0.12 | -$0.34 | -$0.08 | -$0.09 |
| Diluted EPS | -$0.13 | -$0.12 | -$0.34 | -$0.08 | -$0.09 |
| Gain on Sale of Security | – | – | -$1.20M | -$736,000.00 | -$292,000.00 |
| -Less:Impairment of Capital Assets | – | – | $0.00 | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total Assets | $470.43M | $300.35M | $343.32M | $343.32M | $316.55M |
| Total Current Assets | $461.43M | $282.25M | $324.65M | $324.65M | $299.95M |
| Cash and Cash Equivalents & Short-Term Investments | $455.41M | $276.58M | $319.77M | $319.77M | $297.34M |
| -Cash and Cash Equivalents | $455.41M | $276.58M | $319.77M | $319.77M | $297.34M |
| Prepaid Assets | $5.07M | $4.02M | $3.43M | $3.43M | $1.65M |
| Restricted Cash | $0.00 | $449,000.00 | $449,000.00 | $449,000.00 | $449,000.00 |
| Current Deferred Assets | $110,000.00 | $195,000.00 | $195,000.00 | $195,000.00 | $57,000.00 |
| Other Current Assets | $851,000.00 | $1.01M | $802,000.00 | $802,000.00 | $456,000.00 |
| Total Non-Current Assets | $9.00M | $18.10M | $18.67M | $18.67M | $16.60M |
| Net PPE | $8.73M | $15.61M | $16.18M | $16.18M | $14.27M |
| -Gross PPE | $13.98M | $20.58M | $20.86M | $20.86M | $18.65M |
| -Accumulated Depreciation | -$5.25M | -$4.97M | -$4.68M | -$4.68M | -$4.39M |
| Other Non-Current Assets | $270,000.00 | $2.50M | $2.50M | $2.50M | $2.34M |
| Total Liabilities | $83.17M | $88.41M | $96.38M | $96.38M | $97.57M |
| Total Current Liabilities | $25.98M | $20.10M | $26.55M | $26.55M | $28.63M |
| Payables | $9.16M | $4.56M | $6.28M | $6.28M | $5.44M |
| -Accounts Payable | $9.16M | $4.56M | $6.28M | $6.28M | $5.44M |
| Current Accrued Expenses | $9.92M | $9.94M | $8.21M | $8.21M | $9.04M |
| Short-Term Debt and Capital Lease Obligation | $1.16M | $1.82M | $1.87M | $1.87M | $1.67M |
| -Current Capital Lease Obligation | $1.16M | $1.82M | $1.87M | $1.87M | $1.67M |
| Other Current Liabilities | $355,000.00 | $784,000.00 | $777,000.00 | $777,000.00 | $1.65M |
| Total Non-Current Liabilities | $57.19M | $68.31M | $69.83M | $69.83M | $68.93M |
| Long Term Debt and Capital Lease Obligation | $55.55M | $66.73M | $68.28M | $68.28M | $67.36M |
| -Long Term Debt | $49.26M | $48.96M | $50.11M | $50.11M | $50.85M |
| -Long Term Capital Lease Obligation | $6.29M | $17.77M | $18.17M | $18.17M | $16.51M |
| Other Non-Current Liabilities | $1.64M | $1.58M | $1.55M | $1.55M | $1.58M |
| Total Equity | $387.27M | $211.94M | $246.94M | $246.94M | $218.99M |
| Stockholders' Equity | $387.27M | $211.94M | $246.94M | $246.94M | $218.99M |
| Capital Stock | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 |
| -Common Stock | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 | $3,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.19B | $964.67M | $958.43M | $958.43M | $903.58M |
| Retained Earnings | -$800.35M | -$753.71M | -$711.30M | -$711.30M | -$683.45M |
| Gains/Losses Not Affecting Retained Earnings | $769,000.00 | $985,000.00 | -$192,000.00 | -$192,000.00 | -$1.14M |
| Current Deferred Liabilities | – | – | $0.00 | $0.00 | $5.49M |
Cash flow
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$40.43M | -$40.88M | -$93.09M | -$26.72M | -$24.17M |
| Net cash flow from continuing operations | -$40.43M | -$40.88M | -$93.09M | -$26.72M | -$24.17M |
| Net Income from Continuing Operations | -$46.64M | -$42.41M | -$109.00M | -$27.85M | -$32.73M |
| Depreciation & Depletion & Amortization | $291,000.00 | $295,000.00 | $1.15M | $299,000.00 | $286,000.00 |
| Other Non-Cash Items | -$4.66M | $344,000.00 | $5.63M | $3.64M | $673,000.00 |
| Change in Working Capital | $4.77M | -$4.65M | -$5.37M | -$7.07M | $4.03M |
| -Change in Prepaid Assets | -$645,000.00 | -$794,000.00 | -$1.73M | -$2.14M | $971,000.00 |
| -Change in Payables and Accrued Expense | $5.42M | -$3.86M | $6.14M | $548,000.00 | $3.06M |
| Net cash flow from investing | $1,000.00 | -$3.02M | -$604,000.00 | -$247,000.00 | -$48,000.00 |
| Net Cash Flow from Continuing Investing Activities | $1,000.00 | -$3.02M | -$604,000.00 | -$247,000.00 | -$48,000.00 |
| Net PPE Purchase and Sale | $1,000.00 | -$24,000.00 | -$738,000.00 | -$250,000.00 | -$108,000.00 |
| Net Intangibles Purchase and Sale | $0.00 | -$3.00M | – | – | – |
| Financing Cash Flow | $216.66M | $711,000.00 | $274.59M | $49.56M | $8.80M |
| Net Cash Flow from Continuing Financing Activities | $216.66M | $711,000.00 | $274.59M | $49.56M | $8.80M |
| Proceeds from Stock Option Exercised | $441,000.00 | $692,000.00 | $1.38M | $1.02M | $281,000.00 |
| Net Other Financing Charges | $75,000.00 | $19,000.00 | -$337,000.00 | -$57,000.00 | -$271,000.00 |
| Ending Cash Balance | $455.57M | $279.34M | $322.53M | $322.53M | $299.94M |
| Net Change in Cash | $176.23M | -$43.19M | $180.90M | $22.59M | -$15.42M |
| Beginning Cash Balance | $279.34M | $322.53M | $141.64M | $299.94M | $315.36M |
| Free Cash Flow | -$40.42M | -$43.90M | -$93.83M | -$26.97M | -$24.27M |
| Gain/Loss from Continuing Operations | – | – | $1.20M | $736,000.00 | $292,000.00 |
| -Change In Other Working Capital | – | – | -$9.77M | -$5.49M | $0.00 |
| Net Other Investing Changes | – | – | $134,000.00 | $3,000.00 | $60,000.00 |
| Net Issuance Payments Of Debt | – | – | $9.24M | $0.00 | – |
| Net Common Stock Issuance | – | – | $264.31M | $48.59M | -$454,000.00 |
No comments yet — be the first to weigh in on TSHA.
Sign in to join the discussion.